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Summary 
More than one-half of adults with non-Hodgkin's B cell lymphomas present with low-grade 
follicular lymphomas. These tumor cells are found in dose association with follicular T lymphocytes 
and dendritic cells, suggesting that the surrounding ceils may play a role in the support of follicular 
tumors. Supernatants from activated human peripheral blood lymphocytes  were found to promote 
the in vitro proliferation of follicular tumor cells. This effect was entirely due to interleukin 3 
(IL-3), a factor generally thought to cause the growth and differentiation  of immature hematopoietic 
cells. II.-3 receptors were detected on fresh isolates of all primary follicular cell tumors examined. 
These findings suggest that follicular cell tumors may be dependent in vivo on II.-3 and that 
therapies directed against I1.-3, its receptor, or the T cells that produce it may be effective treatment 
for follicular lymphoma. 
F 
hollicular lymphoma, one of the most common hemato- 
logic malignancies in humans, is usually an indolent al- 
though ultimately fatal disease in which the tumor cells grow 
in close proximity to T  cells and follicular dendritic cells. 
The median survival for all patients with follicular lymphoma 
is >6 yr (1). For the majority of patients with follicular lym- 
phoma, transformation to a diffuse large cell lymphoma signals 
the onset of a much more aggressive form of the disease in 
which the tumor cells appear no longer to require T  cells 
or follicular dendritic cells. In these patients, median survival 
drops to <3 yr (1). Unfortunately, the biology of follicular 
lymphoma and the etiology of transformation from follic- 
ular lymphoma to the more aggressive large cell lymphoma 
have been difficult to study because  of the low success rate 
in deriving cell lines in vitro. In this report, we show that 
the in vitro growth of some follicular lymphomas is depen- 
dent upon provision of IL-3. 
Materials  and Methods 
Cytokines and Antibodies.  Human rlL-1-6 were purchased from 
Amgen Biotogicals  (Thousand Oaks, CA). Supematant from PHA- 
P-activated human lymphocytes was prepared as described (2, 3). 
Neutralizing rabbit anti-Ib3s was obtained from R & D Systems, 
Inc. (Minneapolis, MN). Expression of IL-3Rs was detected  by flow 
cytometry using reagents from R & D System, Inc. The BL an- 
tiidiotype was prepared as described (4). FITC-conjugated goat 
anti-mouse  Ig,  PE-conjugated goat anti-mouse  Ig,  and FITC- 
conjugated rabbit anti-human Ig were obtained from Tago, Inc. 
(Burlingame, CA). 
Cells.  The BLT cell line was generated as follows. A female 
patient presented  in 1980 with progressive  lymphadenopathy.  Lymph 
node biopsy in 1981 revealed follicular lymphoma, small cleaved 
type. The patient was treated with combined chemotherapy be- 
tween 1981 and 1983 with partial response and received antiidio- 
type immunotherapy and plasmapheresis in 1983. A splenectomy 
was performed in 1984. A single cell suspension was prepared and 
aliquots frozen in liquid nitrogen in RPMI 1640 supplemented  with 
10% DMSO and 20% FCS. Analysis  of thawed cells revealed  60% 
to be tumor B cells, as judged by antiidiotype staining, and the 
remainder to be T cells. After thawing, spleen cells were cultured 
in medium supplemented with 10%  supernatant from PHA-P- 
activated peripheral lymphocytes. Growth was observed after ~8 
wk. All other tumor cells were obtained as fresh or frozen samples 
of spleen or lymph node. 
Tumor Cell Growth.  Proliferation  ([3H]thymidine  incorporation 
as mean cpm + SE of 12 replicates) of BLT cells or primary tumor 
cells was determined as follows. 3  x  llY BLT cells or 104 primary 
tumor cells were cultured in round-bottomed microtiter wells in 
RPMI 1640 supplemented with 15% FCS (HyClone Laboratories, 
Ogden, UT) and 2 mM t-glutamine for 7 d. Cultures were pulsed 
with 1 #Ci [3H]thymidine for 16 h before harvest and counted in 
a scintillation counter, rlL-3 was added at a final  concentration of 
10 U/ml unless otherwise indicated. Supernatant from activated 
PBL was added at  10% final concentration. 
Results 
A  cell line designated BLT was established  by culturing 
previously frozen spleen  cells isolated from a patient with 
follicular B cell lymphoma. The growth of this cell line was 
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activated peripheral blood cells (2, 3) (Fig.  1). Exponential 
growth with a doubling time of '~4 d was detected 10 wk 
after the initiation of culture. 
The original splenic tumor expresses  an Ig determinant 
(idiotype) that is unique to that particular tumor. To estab- 
lish the origin of the cultured cell line, cells were analyzed 
for expression of the tumor idiotype and Ig isotype on a FACS  | 
(Becton Dickinson & Co., Mountain View, CA) (Fig.  2). 
The majority of the cells in the BLT cell line expressed the 
tumor idiotype and were surface IgM + . However, a portion 
of the BLT cells were IgM + , idiotype-. This phenotype was 
stable over many months of culture. To test whether the BLT 
cell line was composed of a mixture of tumor and nontumor 
cells, on two occasions,  cells were stained with antiidiotype 
and sorted on a FACS  |  The resulting population (>95% 
idiotype positive) was put back in culture. After 2 wk, the 
profile was nearly identical to that shown in Fig.  2,  with 
only "~75%  of the cells staining with antiidiotype. Thus, 
the idiotype-negative population may be due to selective loss 
of the idiotype determinant during culture or to the out- 
growth of a second idiotype-negative population.  Further 
confirmation that the cell line was derived from the original 
tumor came from Southern analyses of the Ig rearrangements. 
Identically rearranged bands were detected in the original 
tumor and the BLT cell line, but not PBL, using probes specific 
for C~ and J, (not shown). Finally,  the t(14;18)  transloca- 
tion typical of most follicular lymphomas was present in both 
the original tumor and the BLT cell line (not shown). 
As described above,  the BLT tumor line was established 
in media supplemented with  supernatants from mitogen- 
activated PBL. Attempts to grow the cell line in the absence 
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Figure 1.  Growth of the BLT follicular tumor cell lines requires super- 
natants from mitogen-activated  peripheral blood cells. BLT cells (106/ml) 
were washed twice in PBS and cultured in three 2-ml wells in the absence 
(@) or presence (VI) of 10% supernatant from PHA-P-activated peripheral 
blood cells; Aliquots were removed daily and assessed for viability by trypan 
blue exclusion. Cultures were supplemented  with fresh media every 3 d 
and split  as necessary. 
of these supernatants were unsuccessful, indicating that growth 
of the BLT tumor line required factors produced by activated 
white blood cells. To determine which, if any, known mole- 
cules stimulated the growth of this follicular tumor cell line, 
BLT tumor cells were cultured in the presence of a panel of 
recombinant human cytokines, and [3H]thymidine incorpo- 
ration was  assessed (Fig.  3 A).  II-3  induced proliferation 
equivalent to that caused by PBL supernatants. In contrast, 
I1-1, -2,  -4, -5,  and -6 did not cause increased [3H]thymi- 
dine incorporation relative to the medium alone. Moreover, 
various combinations of Ibl-6 did not result in any altera- 
tion in the pattern of proliferation induced by each interleukin 
alone (not shown). 
Supernatants from activated PBL contain many molecules 
other than I1"1-6  (4).  To test whether the proliferation of 
the BLT line in response to activated PBL medium was solely 
in response to I1"3, neutralizing antibodies were added to 
the proliferation assays (Fig. 3 B). [3H]Thymidine incorpo- 
ration was completely abrogated when anti-I1"3  antibodies 
were added to cultures supplemented with either activated 
PBL supernatant or riD3. These data demonstrate that the 
in vitro proliferation of the BLT follicular lymphoma cell line 
is dependent upon I1-3. 
Although the BLT cell line is dearly derived from the pri- 
mary follicular tumor, it remained possible that the stimula- 
tory effect of I1-3 on cell proliferation was unique to that 
cultured cell line. Therefore, the effects ofrI1"3 and activated 
PBL supernatants on the in vitro proliferation of a panel of 
primary follicular lymphomas was examined. In all four cases 
tested, addition of activated PBL supernatants or rll~3 resulted 
in marked increases in [3H]thymidine incorporation relative 
to that induced by medium alone (Table 1). To ensure that 
the proliferating cells were in fact tumorous, a case was selected 
for which a mAb specific for the tumor idiotype was avail- 
able. Cells were obtained from excised spleen and cultured 
for 4-6 wk in medium supplemented with ri1-3 or with PHA- 
activated T cell supernatant (Fig. 4). Cells cultured with I1-3 
were 100%  positive for staining with the antitumor idio- 
type antibody, whereas only T  cells were detectable in par- 
allel cultures grown for 4-6 wk in the presence of T cell su- 
pernatants containing I1"2. In our experience, the ability of 
supernatants from activated T  cells to promote the growth 
of T  cells or tumor cells can vary for each patient sample. 
ri1-3 did not have any effect on the proliferation of periph- 
eral blood cells and normal splenocytes (Table 1), or a variety 
of other primary B cell tumors, including diffuse large cell, 
Burkitt's, and chronic lymphocytic leukemias (not shown). 
Moreover, all samples of primary follicular lymphomas tested 
expressed high levels of I1"3Rs  (Fig.  5). The single case of 
large cell lymphoma that was examined was also positive for 
expression of IL-3Rs.  In contrast, PBL and normal spleno- 
cytes were negative. Two-color FACS  |  analysis was used to 
show that in a sample of fresh follicular lymphoma, all cells 
that expressed I1-3tks  coexpressed Ig (Fig.  6).  In contrast, 
a sample of primary Burkitt's lymphoma was surface Ig posi- 
tive, but I1-3R negative (Fig.  6).  Expression of IL-3Rs  on 
an extended panel of other types of primary tumors has not 
been examined. 
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Figure 2.  Expression of tumor-specific idiotype by the 
primary tumor and BLT tumor cell line. Previously frozen 
spleen cells containing the primary tumor (left) or the BLT 
tumor line (right) were stained with murine mAbs specific 
for HLA-dass I (W632), IgM (1D12), the tumor idio- 
type (BL anti-id), and an isotype-matched negative con- 
trol (3'1 control). After washing, cells were stained with 
FITC-conjugated goat anti-mouse Ig and analyzed on a 
FACS IV  |  (Becton Dickinson & Co.).  The spleen cells 
(left) are a mixture of tumor and nontumor  cells, whereas 
the BLT cell line (right) is largely tumor cells. 
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Discussion 
The finding that IL3 induced proliferation of follicular lym- 
phoma cells in vitro is surprising.  IL-3, also known as multi- 
colony stimulating factor (M-CSF),  has been demonstrated 
to promote the survival,  proliferation, and development  of 
multi-potential hematopoietic stern cells and committed pro- 
genitor cells of the granulocyte/macrophage,  erythroid, eo- 
sinophil,  megakaryocyte,  mast cell,  and basophile lineages 
(5-8). IL-3 also enhances myeloid end-cell functions, such as 
phagocytosis,  antibody-dependent cellular  cytotoxicity, and 
monocyte  cytotoxidty  (9-12).  Recently,  Le Bien  and  co- 
workers showed that both normal and leukemic human B 
cell precursors proliferate  to IL-3. Follicular  lymphomas are 
tumors of mature B cells, as judged by their functionally rear- 
ranged Ig genes and cell surface expression of Ig (14-16). How- 
ever, it appears that the t(14;18)  translocafion  of follicular 
lymphoma cells occurs at the pre-B cell stage (17-19).  The 
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Figure 3.  IL-3  stimulates the in vitro proliferation of both the BLT fol- 
licular call line and fresh follicular tumor cells. (.4) [3H]Thymidine in- 
corporation by the BLT follicular cell line. (B) Anti-IL-3 antibody abrogates 
BLT proliferation induced by either rib3 or supernatant  from activated 
peripheral blood cells. 10 U anti-IL-3 (+); no antibody (-). Supernatants 
were added at a final concentration of 10% (filled bars) or 5% (open bars); 
lymphokines were added at a final concentration of 10 U/ml (filled bars) 
or 1 U/ml (open bars). 
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Table  1.  Recombinant 11,-3 Stimulates Proliferation of Primary 
Follicular L ymphoma  Tumors in  Vitro 
[3H]TdR incorporation 
Medium  IL-1 IL-2  IL-3  IL-4 IL-5 IL-6 
~pm 
Lymph node 1"  506  613  411  10,121  581  543  627 
Lymph node 2  318  416  309  8,546  475  408  684 
Lymph node 3  744  755  672  12,321  519  572  689 
Lymph node 4  692  582  543  843  622  927  874 
Spleen 1  543  619  892  7,246  629  613  811 
Spleen 2  813  724  547  1,013  564  508  714 
PBL  1  567  601  612  697  503  782  897 
PBL  2  394  511  483  524  597  624  759 
* Lymph nodes 1-3 and spleen 1 were shown by pathologic examination 
to contain 60-80% follicular lymphoma cells. Lymph node 4 contained 
diffuse large cell lymphoma cells, while spleen 2 and PBL 1 and 2 were 
obtained from normal individuals. n- 
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Figure 4.  Follicular lymphoma cells grown in culture  for 6 wk in medium supplemented with II_,3 express tumor idiotype. Cells isolated from 
the spleen of a patient with follicular lymphoma were grown in medium supplemented with 100 U/ml II,-3 (A-E) or 10% PHA-activated T cell 
supernatant  (F-J).  Cells were stained with an irrelevant antibody (A and F), OKT3 (B and G), anti-K (C and/-/), anti-/x (D and/), or antiidiotype 
(E and J),  followed by FITC-conjugated  goat  anti-mouse Ig. 
chromosomal breaks are focused at the 5' ends of J. regions 
of the Ig genes, suggesting that the translocation occurred 
during attempted heavy chain joining at the pre-B cell stage. 
Thus, it is tempting to speculate that follicular lymphomas 
have retained some specific characteristics of pre-B cells, such 
as the ability to respond to Ib3. 
Independent evidence supports the notion that T cells and 
T  cell-derived factors may be involved in the maintenance 
or proliferation of follicular lymphoma tumors. Both CD4 + 
and CD8 + T cells are found in intimate association with fol- 
licular lymphoma cells in vivo (1). It has been suggested that 
these T cells might facilitate the neoplastic process or mount 
an immune response against it (20). Umetsu et al. (21) showed 
that  an  HLA-DR-specific  CD4 §  T  cell  clone  induced 
proliferation  of some  follicular lymphoma cells  in  vitro. 
Hoelzer and colleagues (22) recently conducted a clinical trial 
using II.-3 in patients with normal hematopoiesis or bone 
marrow failure. 19 patients with advanced tumors were treated 
with IL-3 to assess its toxicity and biological effects. Of these, 
four patients had either follicular or large cell lymphomas. 
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Figure S.  Follicular lymphoma cells 
express  ILo3Rs. Cells  isolated  from 
lymph nodes from patients with follic- 
ular lymphoma (A-C), large cell lym- 
phoma (D), an EBV-transformed  B cell 
line (E), or PBL from a normal donor 
(F) were labeled  with biotin-conjugated 
IL-3  followed  by  FITC-conjugated 
avidin and analyzed for fluorescence on 
an FACS IV  ~  (Becton Dickinson & 
Co.). Background staining was assessed 
using FITC-conjugated  avidin alone. 
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Figure 6.  Coexpression  of [b3Rs and Ig by a primary follicular  tumor Cells isolated  from  lymph  nodes of a patient diagnosed  with follicular  lym- 
phoma (A-D) or Burkitt's lymphoma  (E-H) were analyzed  for expression of surface Ig and Ib3Rs. 
Two of these patients experienced significant progression of 
their disease while receiving II~3. The progression reversed 
spontaneously when IL-3 was discontinued. 
Collectively, these results indicate a prominent role for IL-3 
in the biology of follicular tumors and imply that therapies 
directed against Ib3, its receptor,  or the T cells that produce 
it may prove effective for these clinically important human 
tumors. 
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